The relevance of oncogenes as prognostic markers in cervical cancer

To study the prevalence of the oncogenes c-myc, IFN-α; c-erbB2; H-ras codon 12, 13, and 61; c-fos; and E6/E7 oncogenes of human papillomavirus (HPV) 16 in patients with invasive carcinoma of the cervix and their prognostic significance, genomic DNA and RNA were isolated from tissues of 275 patients in Singapore with nonmetastatic cervical cancer and 32 patients with normal cervix. The levels of expression of the various oncogenes were quantified by PCR using the respective primers. When the PCR data on the DNA were analyzed by the log-rank test, IFN γ (P = 0.02) and H-ras codon 12 and 13 (P = 0.02) were found to be prognostic. In the multivariate analysis, a statistically significant trend for increasing risk with higher quartiles was found for c-myc (P = 0.007) and c-erbB2 (P = 0.03). After adjusting for age and stage, a correlation appears between the amplification of the oncogenes c-myc, c-erbB2, and H-ras codon 12, 13, and 61 and the development of recurrent cervical cancer. Further adjustment to include the parameters of treatment and histology type did not change the outcome of the correlation observed.

[1]  K. Hui,et al.  Characterization of a novel IRF-1-deficient mutant cell line , 2004, Immunogenetics.

[2]  B N Bundy,et al.  Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  B N Bundy,et al.  Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. , 1999, The New England journal of medicine.

[4]  P J Eifel,et al.  Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. , 1999, The New England journal of medicine.

[5]  M. J. van de Vijver,et al.  Oncogene alterations in carcinomas of the uterine cervix: overexpression of the epidermal growth factor receptor is associated with poor prognosis. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[6]  K. Blank,et al.  Concurrent Cisplatin-Based Radiotherapy and Chemotherapy for Locally Advanced Cervical Cancer , 1999 .

[7]  E. Tartour,et al.  Prognostic value of intratumoral interferon gamma messenger RNA expression in invasive cervical carcinomas. , 1998, Journal of the National Cancer Institute.

[8]  G. Flannelly,et al.  Prognostic factors in surgically treated stage IB-IIB carcinoma of the cervix with negative lymph nodes. , 1998, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

[9]  S. Sanz,et al.  The prognostic value of HER-2/neu oncogene in cervical cancer. , 1997, Annals of clinical and laboratory science.

[10]  L. Huang,et al.  Phase I study of immunotherapy of cutaneous metastases of human carcinoma using allogeneic and xenogeneic MHC DNA–liposome complexes , 1997, Gene Therapy.

[11]  A. Sabichi,et al.  Molecular characterization of adenocarcinoma of the cervix. , 1997, Gynecologic oncology.

[12]  T. Nakano,et al.  Correlation of cervical carcinoma c‐erb B‐2 oncogene with cell proliferation parameters in patients treated with radiation therapy for cervical carcinoma , 1997, Cancer.

[13]  S. Lam,et al.  c-fos overexpression is associated with the pathoneogenesis of invasive cervical cancer. , 1997, Gynecologic and Obstetric Investigation.

[14]  M. Rogers,et al.  C-myc mutation detected by polymerase chain reaction--heteroduplex in cervical cancer. , 1997, Gynecologic and obstetric investigation.

[15]  M. Mohiuddin,et al.  Expression and mutation of H-ras in uterine cervical cancer. , 1996, Gynecologic Oncology.

[16]  S. Lam,et al.  Frequent ras gene mutations in squamous cell cervical cancer. , 1995, Cancer letters.

[17]  J. Bidwell,et al.  Detection of β‐thalassaemia mutations using DNA heteroduplex generator molecules , 1995 .

[18]  S. Hirohashi,et al.  Prognostic significance of the overexpression of c‐erbB‐2 protein in adenocarcinoma of the uterine cervix , 1994, Cancer.

[19]  K. Hui,et al.  Locus-specific transcriptional control of HLA genes. , 1992, Journal of immunology.

[20]  T. Iwasaka,et al.  Detection of human papillomavirus genome and analysis of expression of c-myc and Ha-ras oncogenes in invasive cervical carcinomas. , 1992, Gynecologic oncology.

[21]  D. Kerr,et al.  No correlation between ras, c-myc and c-jun proto-oncogene expression and prognosis in advanced carcinoma of cervix. , 1992, European journal of cancer.

[22]  J. Bourhis,et al.  Prognostic value of c-myc proto-oncogene overexpression in early invasive carcinoma of the cervix. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  B. Sevin,et al.  Prospective surgical-pathological study of disease-free interval in patients with stage IB squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. , 1990, Gynecologic oncology.

[24]  K. Hatch,et al.  Amplification of the c‐myc proto‐oncogene in cervical carcinoma , 1988, Journal of surgical oncology.

[25]  P. Gariglio,et al.  High correlation between molecular alterations of the c-myc oncogene and carcinoma of the uterine cervix. , 1987, Cancer research.

[26]  G. Riou,et al.  C-myc PROTO-ONCOGENE EXPRESSION AND PROGNOSIS IN EARLY CARCINOMA OF THE UTERINE CERVIX , 1987, The Lancet.

[27]  M. Piver,et al.  Prognostic Significance of Cervical Lesion Size and Pelvic Node Metastases in Cervical Carcinoma , 1975, Obstetrics and gynecology.

[28]  V. Mutolo,et al.  Inibizione dell’attività catalasica da 2,2 dicloro-N-metildietilamina cloridrato , 1954 .